SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017615
Filing Date
2022-11-14
Accepted
2022-11-14 09:02:31
Documents
76
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q casi-20220930x10q.htm   iXBRL 10-Q 1715003
2 EX-10.1 casi-20220930xex10d1.htm EX-10.1 295895
3 EX-31.1 casi-20220930xex31d1.htm EX-31.1 12629
4 EX-31.2 casi-20220930xex31d2.htm EX-31.2 12463
5 EX-32.1 casi-20220930xex32d1.htm EX-32.1 7181
6 EX-32.2 casi-20220930xex32d2.htm EX-32.2 7236
  Complete submission text file 0001558370-22-017615.txt   7563771

Data Files

Seq Description Document Type Size
7 EX-101.SCH casi-20220930.xsd EX-101.SCH 54112
8 EX-101.CAL casi-20220930_cal.xml EX-101.CAL 63875
9 EX-101.DEF casi-20220930_def.xml EX-101.DEF 190301
10 EX-101.LAB casi-20220930_lab.xml EX-101.LAB 342875
11 EX-101.PRE casi-20220930_pre.xml EX-101.PRE 311931
70 EXTRACTED XBRL INSTANCE DOCUMENT casi-20220930x10q_htm.xml XML 1407310
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-20713 | Film No.: 221380892
SIC: 2836 Biological Products, (No Diagnostic Substances)